skip to content
 

Dr Maria Joáo Correia Pinto Carvalho de Matos

Research Interests 

Currently: My current research interests lie at the interface of Chemistry and Biology, with applications to Biomedicine. I have been working for the last two years in protein conjugation for the development of efficient chemoselective methods compatible with biological systems and their capacity for redesigning the structure and function of proteins of biological and therapeutic interest. 

Previous years: My previous research experience focused on Medicinal Chemistry and Drug Discovery, especially during the early stages of the process. The major projects I was involved in included the design and development of new strategies to direct synthesis, as well as pharmacological studies of natural product-based compounds with potential applications to neurodegenerative diseases. To that end, I was part of theoretical and experimental studies, specifically functioning in the design, synthesis, characterization and biological screening of new pharmacologically active compounds based on different heterocyclic scaffolds. 

 

Publications 

Journal Papers Refereed

77. Coumarins and adenosine receptors: new perceptions in structure-affinity relationships (Fonseca A, Matos MJ, Vilar S, Kachler S, Klotz K-N, Uriarte E, Borges F*) Chem Biol Drug Des 201891, 245-256doi: 10.1111/cbdd.13075.

76. Coumarins as promising scaffold for the treatment of age-related diseases – an overview of the last five years (Delogu G, Matos MJ*Curr Top Med Chem 2018 accepted Doi: 10.2174/1568026618666171215094029.

75. Chemoselective Installation of Amine Bonds on Proteins Through Aza-Michael Ligation (Freedy AM, Matos MJ, Boutureira O, Corzana F, Guerreiro A, Akkapeddi P, Somovilla VJ, Rodrigues T, Nicholls K, Xie B, Jiménez-Osés G, Brindle KM, Neves AA, Bernardes GJL*) JACS 2017, 139, 18365-18375. DOI: 10.1021/jacs.7b10702.

74. Coumarin versus chromone monoamine oxidase B inhibitors: Quo vadis? (Fonseca A, Reis J, Silva TB, Matos MJ, Bagetta D, Ortuso F, Alcaro S, Uriarte E, Borges F*) J Med Chem 2017, 60(16), 7206-7212. DOI: 10.1021/acs.jmedchem.7b00918.

73. MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study and docking calculations (Delogu GL*, Pintus F, May L, Matos MJ, Vilar S, Munín J, Fontenla JA, Hripcsak G, Borges F, Viña D) MedChemComm 2017, 8, 1788-1796. Doi: 10.1039/C7MD00311K.

72. In silico genotoxicity of coumarins: application of Phenol-Explorer food database to functional food science (Guardado Yordi E*, Matos MJ, Pérez Martínez A, Tornes AC, Santana L, Molina E, Uriarte E) RSC Food & Function 2017, 8, 2958-2966. Doi: 10.1039/C7FO00402H.

71. New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: anti-melanogenesis and antioxidant activities, and computational molecular modeling studies (Pintus F, Matos MJ*, Vilar S, Hripcsak G, Varela C, Uriarte E, Santana L, Borges F, Medda R, Di Petrillo A, Era B, Fais A) Bioorg Med Chem 2017, 25, 1687-1695 DOI: 10.1016/j.bmc.2017.01.037.

70. Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins (Robledo-O´Ryan N, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Moncada-Basualto M, Mura F, Lapier M, Maya JD, Olea-Azar C*) Bioorg Med Chem 2017, 25, 621-632 DOI: 10.1016/j.bmc.2016.11.033.

69. Trends in therapeutic drug conjugates for bacterial diseases: a patent review (Cal PMSD, Matos MJ*, Bernardes GJL) Exp Opin Therap Pat 2017, 27(2), 179-189. DOI: 10.1080/13543776.2017.1259411.

68. Heterocyclic antioxidants in nature: coumarins (Matos MJ*, Vazquez-Rodriguez S, Fonseca A, Uriarte E, Santana L, Borges F) Curr Org Chem 2017, 21(4), 311-324. DOI: 10.2174/1385272820666161017170652.

67. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents (Bernardim B, Cal PMSD, Matos MJ, Oliveira B, Martínez-Sáez N, Albuquerque I, Burtoloso A, Jiménez-Osés G, Bernardes GJL*) Nature Commun 2016, 7, 13128. DOI: 10.1038/ncomms13128.

66. Structural elucidation of a series of 6-methyl-3-carboxamidocoumarins (Fonseca A, Gaspar A, Matos MJ, Gomes LR, Low JN, Uriarte E, Borges F*) Magn Reson Chem 2016, 55(4), 373-378. DOI: 10.1002/mrc.4541.

65. 6-Methylcoumarin-N-(quinolin-6-yl)-3-carboxamide: crystal structure and Hirshfeld surface analysis (Gomes LR, Low JN,* Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 1121-1125. doi: 10.1107/S2056989016011026.

64. Evaluation of antioxidant and antitrypanosomal properties of a selected series of synthetic 3-carboxamidocoumarins (Muñoz A, Fonseca A, Matos MJ*, Uriarte E, Santana L, Borges F, Figueroa R, Olea-Azar C*) ChemistrySelect 2016, 1(15), 4957-4964. DOI: 10.1002/slct.201601336.

63. Crystal structures of three 6-substituted coumarin-3-carboxamide derivatives (Gomes LR, Low JN*, Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 926-932. doi.org/10.1107/S2056989016008665.

62. Exploring coumarin potentialities: development of new MAO-B inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold (Fonseca A, Matos MJ, Reis J, Duarte Y, Gutiérrez M, Santana L, Uriarte E, Borges F) RSC Adv 2016, 6, 49764-49768. doi: 10.1039/c6ra05262b.

61. 2-Phenylbenzofuran derivatives as butyrylcholinesterase inhibitors: synthesis, biological activity and molecular modeling (Delogu G, Matos MJ, Fanti M, Era B, Medda R, Pieroni E, Fais A*, Kumar A*, Pintus F) Bioorg Med Chem Lett 2016, 26, 2308-2313. doi: 10.1016/j.bmcl.2016.03.039.

60. Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core (Matos MJ*, Vilar S, Kachler S, Vazquez-Rodriguez S, Varela C, Delogu G, Hripcsak G, Santana L, Uriarte E, Klotz KN, Borges F) MedChemComm 2016, 7, 845-852. doi: 10.1039/C5MD00573F.

59. Facing Chagas’ disease: trypanocidal properties of new coumarin-chalcone scaffolds (Vazquez-Rodriguez S*, Figueroa Guíñez R, Matos MJ, Olea-Azar C, Maya JD, Uriarte E, Santana L, Borges F) Med Chem 2016, 12(6), 537-543. doi: 10.2174/1573406412666160107111809.

58. 3-Amidocoumarins as potential multifunctional agents against neurodegenerative diseases (Matos MJ*, Rodríguez-Enríquez F, Borges F*, Santana L, Uriarte E, Estrada M, Rodríguez-Franco MI, Laguna R, Viña D*) ChemMedChem 2015, 10, 2071-2079. doi: 10.1002/cmdc.201500408. 

57. Design and discovery of tyrosinase inhibitors based on the coumarin scaffold (Matos MJ*, Varela C, Vilar S, Hripcsak G, Borges F, Santana L, Uriarte E, Fais A, Di Petrillo A, Pintus F, Era B) RSC Adv 2015, 5, 94227-94233. doi: 10.1039/C5RA14465E. 

56. Bioactive coumarins from marine sources: origin, structural features and pharmacological properties (Vazquez-Rodriguez S*, Matos MJ, Borges F, Uriarte E, Santana L) Curr Top Med Chem 2015, 15(17), 1755-1766. doi: 10.2174/1568026615666150427125916. 

55. Design, synthesis and antibacterial study of new potent and selective coumarin–chalcone derivatives for the treatment of tenacibaculosis (Vazquez-Rodriguez S*, Lama López R, Matos MJ, Armesto-Quintas G, Serra S, Uriarte E, Santana L, Borges F, Muñoz Crego A, Santos Y) Bioorg Med Chem 2015, 23(21), 7045-7052. doi: 10.1016/j.bmc.2015.09.028. 

54. Synthesis and pharmacological activities of non-flavonoid chromones: a patent review (from 2005-2015) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F) Exp Opin Therap Pat 2015, 25(11), 1-20. doi: 10.1517/13543776.2015.1078790. 

53. Relationship between thermodynamic parameters and genotoxicity of bioactive phenolic compounds (Guardado Yordi E*, Matos MJ, Santana L, Uriarte E, Pérez Martínez A, Molina Pérez E) Bri Biomed Bull 2015, 3(3), 317-329. 

52. Natural coumarins: QSRT approaches regarding their genotoxicity (Guardado Yordi E*, Matos MJ, Santana L, Uriarte E, Abreu O, Molina Pérez E) Biol Chem Res 2015, 241-257.

51. Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold (Matos MJ*, Vilar S, Kachler S, Celeiro M, Vazquez-Rodriguez S, Santana L, Uriarte E, Hripcsak G, Borges F, Klotz KN) Bioorg Chem 2015, 61, 1-6. doi: 10.1016/j.bioorg.2015.05.008. 

50. Study of coumarin-resveratrol hybrids as potent antioxidant compounds (Matos MJ*, Mura F, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E, Olea-Azar C*) Molecules 2015, 20, 3290-3308. doi: 10.3390/molecules20023290. 

49. Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives (Matos MJ*, Rodríguez-Enríquez F, Vilar S, Santana L, Uriarte E, Hripcsak G, Estrada M, Rodríguez-Franco MI, Viña D) Bioorg Med Chem Lett 2015, 25, 642-648. doi: 10.1016/j.bmcl.2014.12.001. 

48. Oxidative stress and neurodegenerative diseases: looking for a therapeutic solution inspired on benzopyran chemistry (Gaspar A, Milhazes N, Santana L, Uriarte E, Borges F, Matos MJ*) Curr Top Med Chem 2015, 15(5), 432-445. doi: 10.2174/1568026614666141229124141. 

47. The interest of antioxidants agents in parasitic diseases. The case study of coumarins (Figueroa-Guinez R, Matos MJ, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C*, Borges F, Diego Maya J) Curr Top Med Chem 2015, 15(9), 850-856. doi: 10.2174/1568026615666150220113155.

46. In silico clastogenic activity of dietary phenolic acids (Guardado Yordi E*, Matos MJ, Castro Pupo R, Santana L, Uriarte E, Molina Pérez E) LWT Food Sci Tech 2015, 61, 216-223. doi: 10.1016/j.lwt.2014.11.012. 

45. Potential pharmacological uses of chalcones: a patent review (from June 2011-2014) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L) Exp Opin Therap Pat 2015, 25(3), 351-366. doi: 10.1517/13543776.2014.995627. 

44. Insights into the interaction of novel coumarin derivatives with human A3 adenosine receptors (Matos MJ*, Vilar S, Kachler S, Fonseca A, Santana L, Uriarte E, Borges F, Tatonetti NP, Klotz KN) ChemMedChem 2014, 9, 2245-2253 (paper selected as back cover of the issue). doi: 10.1002/cmdc.201402205. 

43. Insights into functional and structural properties of 3-arylcoumarins as an interesting scaffold in MAO-B inhibition (Matos MJ*, Vilar S, García-Morales V, Tatonetti NP, Uriarte E, Santana L, Viña D) ChemMedChem 2014, 9, 1488-1500. doi: 10.1002/cmdc.201300533. 

42. Synthesis and electrochemical study of new 3-(hydroxyphenyl)benzo[f]coumarins (Matos MJ, Janeiro P, Santana L, Uriarte E, Oliveira-Brett AM*) J Electroanal Chem 2014, 726, 62-70. doi: 10.1016/j.jelechem.2014.05.003. 

41. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases (Matos MJ*, Janeiro P, González Franco RM, Vilar S, Tatonetti NP, Santana L, Uriarte E, Borges F, Fontanela JA, Viña D) Fut Med Chem 2014, 6(4), 371-383. doi: 10.4155/fmc.14.9. 

40. Chromone: a valid scaffold in medicinal chemistry (Gaspar A, Matos MJ, Garrido J, Uriarte E, Borges F*) Chem Rev 2014, 114 (9), 4960-4992. doi: 10.1021/cr400265z. 

39. Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives (Figueroa Guíñez R, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C*, Maya JD) Fut Med Chem 2013, 5(16), 1911-1922. doi: 10.4155/fmc.13.147. 

38. Comparative study of the 3-phenylcoumarin scaffold: synthesis, X-ray structural analysis and semiempirical calculations of a selected series of compounds (Matos MJ*, Vilar S, Tatonetti NP, Santana L, Uriarte E) J Mol Struct 2013, 1050, 185-191. doi: 10.1016/j.molstruc.2013.07.037. 

37. Synthesis, electrochemical and biological studies on novel coumarin-chalcone hybrid compounds (Pérez-Cruz F, Vazquez-Rodriguez S*, Matos MJ, Herrera-Morales A, Villamena F, Das A, Gopalakrishnan B, Olea-Azar C, Santana L, Uriarte E) J Med Chem 2013, 56, 6136-6145. doi: 10.1021/jm400546y. 

36. QSAR and complex network recognition of miRNAs in stem cells (Molina E*, Uriarte E, Santana L, Matos MJ, Borges F) Curr Bioinf 2013, 8, 438-451. doi: 2212-392X/13. 

35. Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins (Matos MJ*, Hogger V, Gaspar A, Kachler S, Borges F, Uriarte E, Santana L, Klotz KN) J Pharm Pharmacol 2013, 65, 1590-1597. doi: 10.1111/jphp.12135. 

34. (1S,2S,5S)-2-Methyl-3-oxo-5-(prop-1-en-2-yl)cyclohexane-1-carbonitrile (Rivadulla ML, Fall A, González M, Matos MJ*) Acta Cryst 2013, E69, o799. doi: 10.1107/S1600536813011197. 

33. [(2S,3aR,6aR)-5-Oxohexahydrofuro[3,2-b]furan-2-yl]methyl acetate (González M, Martínez A, Rivadulla ML, Matos MJ*) Acta Cryst 2013, E69, o772. doi: 10.1107/S1600536813010313. 

32. Synthesis of coumarin-chalcone hybrids and evaluation of their antioxidant and trypanocidal properties (Vazquez-Rodriguez S*, Figueroa-Guíñez R, Matos MJ, Santana L, Uriarte E, Lapier M, Maya JD, Olea-Azar C*) MedChemComm 2013, 4, 993-1000. doi: 10.1039/c3md00025g. 

31. MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study and docking calculations (Ferino G, Cadoni E, Matos MJ*, Quezada E, Uriarte E, Santana L, Vilar S, Tatonetti NP, Yáñez M, Viña D, Picciau C, Serra S, Delogu G*) ChemMedChem 2013, 8, 956-966. doi: 10.1002/cmdc.201300048. 

30. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins (Matos MJ*, Pérez-Cruz F, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F, Olea-Azar C) Bioorg Med Chem 2013, 21, 3900-3906. doi: 10.1016/j.bmc.2013.04.015. 

29. Synthesis, NMR characterization, X-ray structural analysis and theoretical calculations of amide and ester derivatives of the coumarin scaffold (Matos MJ*, Uriarte E, Santana L, Vilar S) J Mol Struct 2013, 1041, 144-150. doi: 10.1016/j.molstruc.2013.03.014. 

28. Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists (Vazquez-Rodriguez S*, Matos MJ, Santana L, Uriarte E, Borges F, Kachler S, Klotz KN) J Pharm Pharmacol 2013, 65, 697-703. doi: 10.1111/jphp.12028. 

27. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study (Matos MJ*, Vilar S, Gonzalez-Franco RM, Uriarte E, Santana L, Friedman C, Tatonetti NP, Viña D, Fontenla JA) Eur J Med Chem 2013, 63, 151-161. doi: 10.1016/j.ejmech.2013.02.009. 

26. Synthesis and structure-activity relationships of novel amino/nitro substituted 3-arylcoumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Molecules 2013, 18, 1394-1404. doi: 10.3390/molecules18021394. 

25. New hydroxylated 3-arylcoumarins, synthesis and electrochemical study (Janeiro P, Matos MJ, Santana L, Uriarte E, Oliveira-Brett AM*) J Electroanal Chem 2013, 689, 243-251. doi: 10.1016/j.jelechem.2012.10.020. 

24. Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives (Matos MJ*, Gaspar A, Kachler S, Klotz KN, Borges F, Santana L, Uriarte E) J Pharm Pharmacol 2013, 65, 30-34. doi: 10.1111/j.2042-7158.2012.01571.x.

23. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold (Matos MJ, Viña D, Vazquez-Rodriguez S, Uriarte E, Santana L*) Curr Top Med Chem 2012, 12, 2210-2239. doi: 10.2174/156802612805220002. 

22. Monoamine oxidase inhibitors: ten years of docking studies (Ferino G*, Vilar S, Matos MJ, Uriarte E, Cadoni E) Curr Top Med Chem 2012, 12, 2145-2162. doi: 10.2174/156802612805220048. 

21. N-(2-Oxo-2H-chromen-3-yl)cyclohexanecarboxamide (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o3447-o3448. doi: 10.1107/S1600536812047903. 

20. Improved synthesis of 3-(aminoaryl)coumarins (Matos MJ*, Gaspar A, Borges F, Uriarte E, Santana L) Org Prep Proc Int 2012, 44, 522-526. doi: 10.1080/00304948.2012.730937. 

19. 3-Phenylcoumarin (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o2645. doi: 10.1107/S1600536812034277. 

18. Looking for new targets: simple coumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Med Chem 2012, 8, 1140-1145. doi: 10.2174/157340612804075205. 

17. In search for new chemical entities as adenosine receptor ligands: development of agents based on benzo-γ-pyrone skeleton (Gaspar A, Reis J, Matos MJ, Uriarte E, Borges F*) Eur J Med Chem 2012, 54, 914-918. doi: 10.1016/j.ejmech.2012.05.033. 

16. Monoamino oxidase A: an interesting pharmacological target for the development of multi-target QSAR models (Molina E*, Sobarzo-Sánchez E, Speck-Planche A, Matos MJ*, Uriarte E, Santana L, Yáñez M, Orallo F) Mini Rev Med Chem 2012, 12, 947-958. doi: 10.2174/138955712802762383. 

15. 8-Substituted-3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation and docking studies (Viña D, Matos MJ*, Ferino G, Cadoni E, Laguna R, Borges F, Uriarte E, Santana L) ChemMedChem 2012, 7, 464-470 (According to the Thomson Reuters Web of Science, this Full Paper was among the top 10 most cited articles published by ChemMedChem in 2012). doi: 10.1002/cmdc.201100538. 

14. Tyrosine-like condensed derivatives as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Serra S, Corda M, Fadda MB, Era B, Fais A) J Pharm Pharmacol 2012, 64, 742-746. doi: 10.1111/j.2042-7158.2012.01467.x. 

13. Structural alerts for predicting clastogenic activity of pro-oxidant flavonoid compounds: quantitative structure–activity relationship study (Guardado E*, Molina E, Matos MJ, Uriarte E) J Biomol Screen 2012, 17(2), 216-224. doi: 10.1177/1087057111421623. 

12. Hydroxycoumarins as selective MAO-B inhibitors (Serra S*, Ferino G, Matos MJ, Vázquez-Rodríguez S, Delogu G, Viña D, Cadoni E, Santana L, Uriarte E) Bioor Med Chem Lett 2012, 22, 258-261. doi: 10.1016/j.bmcl.2011.11.020. 

11. 3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer´s disease (Viña D, Matos MJ*, Yáñez M, Santana L, Uriarte E) MedChemComm 2012, 3, 213-218 (Featured in the top 10% of the most highly cited articles published in the latest Impact Factor window 2011-2012). doi: 10.1039/c1md00221j. 

10. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors (Matos MJ*, Terán C, Pérez-Castillo Y, Uriarte E, Santana L, Viña D*) J Med Chem 2011, 54, 7127-7137. doi: dx.doi.org/10.1021/jm200716y. 

9. MAO inhibitory activity modulation: 3-phenylcoumarins versus 3-benzoylcoumarins (Matos MJ, Vázquez-Rodriguez S, Uriarte E, Santana L, Viña D*) Bioorg Med Chem Lett 2011, 21, 4224-4227. doi: 10.1016/j.bmcl.2011.05.074. 

8. New halogenated phenylcoumarins as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Delogu G, Corda M, Fadda MB, Era B, Fais A) Bioorg Med Chem Lett 2011, 21, 3342-3345. doi: 10.1016/j.bmcl.2011.04.012. 

7. Synthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions of 3-chlorocoumarin (Matos MJ*, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E) Tetrahedron Lett 2011, 52, 1225-1227. doi: 10.1016/j.tetlet.2011.01.048. 

6. Regioselective synthesis of different bromo substituted 3-arylcoumarins (Matos MJ*, Delogu G, Podda G, Santana L, Uriarte E) Synthesis 2010, 16, 2763-2766. doi: 10.1055/s-0029-1218835. 

5. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Janeiro P, Borges F, Santana L, Uriarte E) Bioorg Med Chem Lett 2010, 20, 5157-5160. doi: 10.1016/j.bmcl.2010.07.013. 

4. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Picciau C, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 5053-5055. doi: 10.1016/j.bmcl.2009.07.039. 

3. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 3268-3270. doi: 10.1016/j.bmcl.2009.04.085. 

2. Tyrosinase inhibitor activity of the coumarin-resveratrol hybrids (Fais A*, Corda M, Era B, Fadda MB, Matos MJ, Quezada E, Santana L, Picciau C, Podda G, Delogu G) Molecules 2009, 14, 2514-2520. doi: 10.3390/molecules14072514. 

1. Synthesis of regio-isomeric functionalized benzodifurans and angelicins (Quezada E, Delogu G*, Viña D, Podda G, Matos MJ, Picciau C) Helv Chim Acta 2009, 92, 1309-1314. doi: 10.1002/hlca.200800421. 

Patent

Use of 6-substituted 3-phenylcoumarines as selective monoamine oxidase B inhibitors for treating neurodegenerative diseases and obesity and preparation of new derivatives, Number: WO2010086484 A1. Priority country: Spain. Date: 05/08/2010. Titular entity: USC. Authors: Lourdes Santana, Francisco Orallo, Dolores Viña, Maria João Matos, Elías Quezada, Matilde Yañez, Santiago Vilar, Eugenio Uriarte.

Book chapters

1. Ellagic acid: its importance in diet (Yordi E, Martínez AP, Pérez RDA, Molina E, Santana L, Uriarte E, Abreu OA, Matos MJ) 2016 – Chapter 3 pp. 73-110. Ellagic Acid: Food Sources, Potential Role in Human Health and Antioxidant Effects, Edmund Brewer (Ed.), ISBN 978-1-63485-658-4, Nova Science Publishers

2. Coumarins: an important class of phytochemicals (Matos MJ, Santana L, Uriarte E, Abreu O, Molina E, Yordi EG) 2015 – Phytochemicals, Jaouad Bouayed and Torsten Bohn (Ed.), ISBN 978-953-51-4156-3, InTech, http://dx.doi.org/10.5772/59982.

3. Umbelliferone: a natural scaffold suitable for the synthesis of ortho-acetylhydroxycoumarins via Fries rearrangement reaction (Vazquez-Rodriguez S, Matos MJ, Uriarte E, Borges F) 2014 - Comprehensive Organic Chemistry Experiments for the Laboratory Classroom, C.A. Afonso, D.P. Simão (Eds.), 2016, Royal Society of Chemistry, ISBN 9781849739634.

4. Antioxidant and Pro-Oxidant Effects of Polyphenolic Compounds and Structure-Activity Relationship Evidence (Guardado Yordi EG, Molina E, Matos MJ, Uriarte E) 2012 - Nutrition, Well-Being and Health, Jaouad Bouayed and Torsten Bohn (Ed.), ISBN: 978-953-51-0125-3, InTech 

Editorials

1. One-pot catalyzed synthesis of arylamines (Maria João MatosEC Chemistry 2015, 1(2), 67. 

2. Monoamine oxidase as a target in medicinal chemistry and drug discovery (Dolores Viña and Maria João MatosCurrent Topics in Medicinal Chemistry 2012, 12, 2215. doi: 10.2174/1568026611212200001.

Research Group

Telephone number

01223 336698 (shared)

Email address

mm2147@cam.ac.uk